CTEPH
MCID: PLM101
MIFTS: 37

Pulmonary Hypertension, Chronic Thromboembolic, Without Deep Vein Thrombosis (CTEPH)

Categories: Blood diseases, Cardiovascular diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Pulmonary Hypertension, Chronic Thromboembolic, Without Deep Vein...

MalaCards integrated aliases for Pulmonary Hypertension, Chronic Thromboembolic, Without Deep Vein Thrombosis:

Name: Pulmonary Hypertension, Chronic Thromboembolic, Without Deep Vein Thrombosis 57
Pulmonary Hypertension, Chronic Thromboembolic, Without Deep Vein Thrombosis, Susceptibility to 57 13
Chronic Thromboembolic Pulmonary Hypertension 58 70
Cteph, Dvt-Negative, Susceptibility to 57
Cteph, Dvt-Negative 57
Cteph 58

Characteristics:

Orphanet epidemiological data:

58
chronic thromboembolic pulmonary hypertension
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: Adult;

Classifications:

Orphanet: 58  
Rare respiratory diseases


External Ids:

OMIM® 57 612862
UMLS via Orphanet 71 C2363973
Orphanet 58 ORPHA70591
UMLS 70 C2363973

Summaries for Pulmonary Hypertension, Chronic Thromboembolic, Without Deep Vein...

MalaCards based summary : Pulmonary Hypertension, Chronic Thromboembolic, Without Deep Vein Thrombosis, also known as pulmonary hypertension, chronic thromboembolic, without deep vein thrombosis, susceptibility to, is related to chronic thromboembolic pulmonary hypertension and pulmonary hypertension. An important gene associated with Pulmonary Hypertension, Chronic Thromboembolic, Without Deep Vein Thrombosis is CTEPH1 (Pulmonary Hypertension, Chronic Thromboembolic, Without Deep Vein Thrombosis, Susceptibility To). The drugs Selexipag and Treprostinil have been mentioned in the context of this disorder. Affiliated tissues include endothelial, lung and smooth muscle, and related phenotypes are depressivity and fatigue

More information from OMIM: 612862

Related Diseases for Pulmonary Hypertension, Chronic Thromboembolic, Without Deep Vein...

Diseases related to Pulmonary Hypertension, Chronic Thromboembolic, Without Deep Vein Thrombosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 159)
# Related Disease Score Top Affiliating Genes
1 chronic thromboembolic pulmonary hypertension 12.1
2 pulmonary hypertension 11.6
3 pulmonary embolism 11.2
4 pulmonary hypertension, primary, 1 11.2
5 thrombophilia due to thrombin defect 10.9
6 cardiac arrest 10.9
7 vascular disease 10.7
8 pulmonary edema 10.7
9 antiphospholipid syndrome 10.7
10 tricuspid valve insufficiency 10.7
11 thrombosis 10.6
12 syncope 10.6
13 thrombophilia 10.6
14 respiratory failure 10.5
15 lung disease 10.5
16 hemopericardium 10.4
17 pericardial effusion 10.4
18 hypothyroidism 10.4
19 connective tissue disease 10.4
20 sarcoidosis 1 10.4
21 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.4
22 pulmonary disease, chronic obstructive 10.4
23 hydrocephalus 10.4
24 sarcoma 10.4
25 spindle cell sarcoma 10.4
26 pulmonary venoocclusive disease 10.4
27 mediastinitis 10.4
28 vasculitis 10.4
29 fibrosing mediastinitis 10.4
30 cardiogenic shock 10.4
31 arteries, anomalies of 10.3
32 fibrosis of extraocular muscles, congenital, 1 10.3
33 lipoprotein quantitative trait locus 10.3
34 sleep apnea 10.3
35 hepatic veno-occlusive disease 10.3
36 heart disease 10.3
37 thrombocytopenia 10.3
38 congestive heart failure 10.3
39 heritable pulmonary arterial hypertension 10.3
40 sickle cell disease 10.3
41 autoimmune disease 10.2
42 varicose veins 10.2
43 hypertension, early-onset, autosomal dominant, with severe exacerbation in pregnancy 10.2
44 cyanosis, transient neonatal 10.2
45 inflammatory bowel disease 10.2
46 osteomyelitis 10.2
47 nasopharyngitis 10.2
48 portal hypertension 10.2
49 cardiac tamponade 10.2
50 nephrotic syndrome 10.2

Graphical network of the top 20 diseases related to Pulmonary Hypertension, Chronic Thromboembolic, Without Deep Vein Thrombosis:



Diseases related to Pulmonary Hypertension, Chronic Thromboembolic, Without Deep Vein Thrombosis

Symptoms & Phenotypes for Pulmonary Hypertension, Chronic Thromboembolic, Without Deep Vein...

Human phenotypes related to Pulmonary Hypertension, Chronic Thromboembolic, Without Deep Vein Thrombosis:

58 (show all 37)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 depressivity 58 Occasional (29-5%)
2 fatigue 58 Frequent (79-30%)
3 congestive heart failure 58 Very frequent (99-80%)
4 obesity 58 Occasional (29-5%)
5 autoimmunity 58 Occasional (29-5%)
6 inflammation of the large intestine 58 Very rare (<4-1%)
7 neoplasm 58 Very rare (<4-1%)
8 osteomyelitis 58 Very rare (<4-1%)
9 pulmonary embolism 58 Frequent (79-30%)
10 pulmonary arterial hypertension 58 Very frequent (99-80%)
11 syncope 58 Occasional (29-5%)
12 right bundle branch block 58 Occasional (29-5%)
13 reduced vital capacity 58 Frequent (79-30%)
14 elevated c-reactive protein level 58 Occasional (29-5%)
15 abnormality of blood and blood-forming tissues 58 Occasional (29-5%)
16 edema 58 Occasional (29-5%)
17 exertional dyspnea 58 Frequent (79-30%)
18 abnormal t-wave 58 Occasional (29-5%)
19 deep venous thrombosis 58 Frequent (79-30%)
20 antiphospholipid antibody positivity 58 Occasional (29-5%)
21 myeloproliferative disorder 58 Very rare (<4-1%)
22 central sleep apnea 58 Occasional (29-5%)
23 left ventricular dysfunction 58 Occasional (29-5%)
24 palpitations 58 Frequent (79-30%)
25 increased hdl cholesterol concentration 58 Occasional (29-5%)
26 increased pulmonary vascular resistance 58 Very frequent (99-80%)
27 right ventricular failure 58 Occasional (29-5%)
28 lupus anticoagulant 58 Occasional (29-5%)
29 right ventricular dilatation 58 Occasional (29-5%)
30 obstructive deficit on pulmonary function testing 58 Frequent (79-30%)
31 cardiac shunt 58 Occasional (29-5%)
32 recurrent thromboembolism 58 Occasional (29-5%)
33 dysfibrinogenemia 58 Occasional (29-5%)
34 abnormality of von willebrand factor 58 Occasional (29-5%)
35 hypocapnia 58 Occasional (29-5%)
36 right atrial enlargement 58 Occasional (29-5%)
37 increased factor viii activity 58 Occasional (29-5%)

Clinical features from OMIM®:

612862 (Updated 05-Apr-2021)

Drugs & Therapeutics for Pulmonary Hypertension, Chronic Thromboembolic, Without Deep Vein...

Drugs for Pulmonary Hypertension, Chronic Thromboembolic, Without Deep Vein Thrombosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 45)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Selexipag Approved Phase 3 475086-01-2
2
Treprostinil Approved, Investigational Phase 3 81846-19-7 54786 6918140
3
Warfarin Approved Phase 3 81-81-2 54678486 6691
4
Edoxaban Approved Phase 3 480449-70-5
5
Macitentan Approved Phase 3 441798-33-0
6
Ambrisentan Approved, Investigational Phase 3 177036-94-1 6918493
7 Calamus Phase 3
8 Anticoagulants Phase 3
9 Serine Proteinase Inhibitors Phase 3
10 Factor Xa Inhibitors Phase 3
11 Antithrombin III Phase 3
12
protease inhibitors Phase 3
13 Antithrombins Phase 3
14 HIV Protease Inhibitors Phase 3
15 Endothelin Receptor Antagonists Phase 3
16 Endothelin A Receptor Antagonists Phase 3
17 Antihypertensive Agents Phase 3
18
Serine Investigational, Nutraceutical Phase 3 56-45-1 5951
19
Riociguat Approved Phase 2 625115-55-1
20 Radiopharmaceuticals Phase 2
21
Nitric Oxide Approved Phase 1 10102-43-9 145068
22
Iodine Approved, Investigational 7553-56-2 807
23
Thrombin Approved, Investigational
24
Acetylcysteine Approved, Investigational 616-91-1 12035
25
Iloprost Approved, Investigational 78919-13-8 6443959
26
Epoprostenol Approved 35121-78-9, 61849-14-7 5282411 5280427
27
Tadalafil Approved, Investigational 171596-29-5 110635
28
Bosentan Approved, Investigational 147536-97-8 104865
29
Cysteine Approved, Nutraceutical 52-90-4 5862
30
Cadexomer iodine Experimental 94820-09-4
31
Tezosentan Investigational 180384-57-0
32 Hemostatics
33 Coagulants
34 Respiratory System Agents
35 Antidotes
36 Antioxidants
37 Protective Agents
38 Expectorants
39 N-monoacetylcystine
40 Anti-Infective Agents
41 Antiviral Agents
42 Phosphodiesterase 5 Inhibitors
43 Sildenafil Citrate 171599-83-0
44 Fluorodeoxyglucose F18
45 Deoxyglucose

Interventional clinical trials:

(show top 50) (show all 77)
# Name Status NCT ID Phase Drugs
1 CHANGE-MRI (CTEPH DIAGNOSIS Europe - MRI) Unknown status NCT02791282 Phase 3
2 Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Bosentan in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Completed NCT00313222 Phase 3 bosentan
3 Long-term Open-label Extension Study in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Who Completed Protocol AC-052-366 (BENEFIT, NCT00313222) Completed NCT00319111 Phase 3 bosentan
4 Long-term Extension, Multicentre, Multi-international Study to Evaluate the Safety and Tolerability of Oral BAY63-2521 (1mg, 1.5 mg, 2.0 mg, 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH). Completed NCT00910429 Phase 3 Riociguat (Adempas, BAY63-2521)
5 Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Completed NCT00855465 Phase 3 Riociguat (Adempas, BAY63-2521);Placebo
6 Effect of Long-term Oxygen Therapy on Exercise Capacity and Quality of Life in Patients With Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension Completed NCT01884012 Phase 3
7 A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Group-sequential, Adaptive, Phase 3 Study With Open-label Extension Period to Assess the Efficacy and Safety of Selexipag as an add-on to Standard of Care Therapy in Subjects With Inoperable or Persistent/Recurrent After Surgical and/or Interventional Treatment Chronic Thromboembolic Pulmonary Hypertension Recruiting NCT03689244 Phase 3 Selexipag;Placebo
8 A Prospective, Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel Group, Adaptive Phase 3 Study With Open-label Extension to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension Recruiting NCT04271475 Phase 3 Macitentan;Placebo
9 A Double Blind Controlled Clinical Study to Investigate the Efficacy and Tolerability of Subcutaneous Treprostinil Sodium in Patients With Severe Non-operable Chronic Thromboembolic Pulmonary Hypertension (CTREPH) Active, not recruiting NCT01416636 Phase 3 Treprostinil sodium
10 Initial Dual Oral coMbination Therapy Versus Standard-of-care Initial Oral Monotherapy Prior to Balloon Pulmonary Angioplasty in Patients With Inoperable Chronic Thromboembolic Pulmonary hyperTension Not yet recruiting NCT04780932 Phase 2, Phase 3 Macitentan 10mg;Placebo
11 An Investigator-initiated, Phase III Trial, Randomized, Single-blind, Double-dummy, Parallel-group, Multi-center Study for the Evaluation of Efficacy and Safety of Warfarin Versus Edoxaban in Subjects With CTEPH Taking Warfarin: KABUKI Not yet recruiting NCT04730037 Phase 3 Edoxaban;Warfarin Potassium;Warfarin Potassium placebo;Edoxaban placebo
12 A Prospective, Multicenter, Open-label, Single Arm, Phase III Study to Assess the Efficacy and Safety of Macitentan (ACT-064992) in Subjects With Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Terminated NCT03809650 Phase 3 macitentan 10 mg
13 A Randomised, Multicentre, Double-Blind, Placebo-Controlled Study Of Ambrisentan In Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH). Terminated NCT01884675 Phase 3 Ambrisentan 5 mg;Placebo
14 An Open-label Extension Study of the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Terminated NCT01894022 Phase 3 Ambrisentan 5 mg
15 Randomized Pilot Trial of Interventional Treatment of Residual Pulmonary Hypertension in Patients After Pulmonary Thromboendarterectomy Unknown status NCT02745106 Phase 2
16 Evaluation of Right Ventricular Function and Metabolism Following Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension- Images of Rio Completed NCT02094001 Phase 2
17 Effect of Short-term Oxygen Therapy on Cardiopulmonary Exercise Capacity in Patients With Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension Completed NCT01748474 Phase 2
18 Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel-group, 24-week Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension Completed NCT02021292 Phase 2 Macitentan;Placebo
19 Prospective, Randomized, Controlled Trial of the Effect of Long-term Oxygen Therapy on 6-minute Walking Distance, Clinical Parameters and Hemodynamics in Patients With PAH and CTEPH Recruiting NCT04207593 Phase 2 Oxygen
20 The Effect of Riociguat for Peak Cardiac Index on Cardiopulmonary Exercise Test in CTEPH Patients After Normalization of Pulmonary Artery Pressure by Combination Treatment of Riociguat and Balloon Pulmonary Angioplasty Recruiting NCT04600492 Phase 2 Riociguat Oral Tablet
21 MERIT-2 : Long Term, Multicenter, Single-arm, Open-label Extension Study of the MERIT-1 Study, to Assess the Safety, Tolerabilty and Efficacy of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Active, not recruiting NCT02060721 Phase 2 Macitentan
22 A Phase 2, Randomised, Double-Blind, Placebo-Controlled, Multicentre, Prospective Study to Assess Efficacy of Riociguat in Patients With Operable CTEPH Prior to Pulmonary Endarterectomy With High Preoperative Pulmonary Vascular Resistance Terminated NCT03273257 Phase 2 Riociguat;Placebo
23 A Non-randomized Two Part Multi-Center, Open-label, Single Dose Trial With an Escalation Part in Untreated Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Patients (Part A), Followed by a Parallel Group Part in Untreated and Pre-treated Patients With PAH and CTEPH (Part B) to Investigate the Safety, Tolerability and Pharmacodynamics of Inhaled BAY1237592 Recruiting NCT03754660 Phase 1 BAY1237592;PH-monotherapy;PH-combination therapy
24 Prospective Registry to Evaluate the Effective Incidence of Chronic Thromboembolic Pulmonary Hypertension in Germany Unknown status NCT02660463
25 Assessment of Safety and Efficacy of Balloon Pulmonary Angioplasty in Non-operable CTEPH Patients Unknown status NCT02964390
26 Lung Perfusion Measured With Dual-Energy CT (DECT) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Comparative Study With Right Heart Catheterization and Ventilation/Perfusion Scintigraphy (V/Q) Unknown status NCT03450304
27 Gene Mutations in Secondary Pulmonary Hypertension Unknown status NCT00348803
28 IodiNe Subtraction maPpIng in the Diagnosis of chRonic Pulmonary thromboEmbolic Disease (INSPIRE): An Observational Diagnostic Study Unknown status NCT03806907
29 Inspiratory Muscle Training in Patients With Chronic Thromboembolic Pulmonary Hypertension: a Randomized Controlled Trial Unknown status NCT03102294
30 Three-dimensional Echocardiographic Assessment of Right Ventricular Function in Patients Undergoing Pulmonary Endarterectomy Unknown status NCT02426203
31 Local Registry of Patients With Chronic Thromboembolic Pulmonary Hypertension in Novosibirsk Region Unknown status NCT03349164
32 Long-term Right Ventricular Resynchronization Therapy for Chronic Thromboembolic Pulmonary Hypertension Unknown status NCT01163422
33 Russian National Registry of Patients With Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension Unknown status NCT03707561
34 National, Prospective, Multicenter,Observational Registry Study on Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension in China Unknown status NCT01417338
35 Epidemiological Study of Chronic Thromboembolic Pulmonary Hypertension in China Unknown status NCT01717092
36 Assessment of Blood Coagulation Disorders in Patients With Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension. Unknown status NCT03195543
37 Incidence of CTEPH in Dependence of Thrombus Location in Patients With Acute Pulmonary Embolism and Index Fibrinolysis Unknown status NCT01672203
38 Early Non-invasive Detection of CTEPH After Pulmonary Embolism - The InShape-2 Study Completed NCT02555137
39 United States CTEPH Registry Completed NCT02429284
40 New International CTEPH Database Completed NCT02656238
41 The Right Ventricle in Chronic Pressure Overload: Identifying Novel Molecular Targets for Functional Imaging Completed NCT03199131
42 A Prospective Single Blind Controlled Study to Assess the Efficacy of a Lung Protective Ventilation Strategy in the Prevention of Reperfusion Lung Injury Following PTE Completed NCT00747045
43 Identification Of The Predictive Angiographic And Computed Tomographic (CT) Criteria Of The Success Of The Thromboendarterectomy In Chronic Pulmonary Hypertension Completed NCT00657722
44 Riociguat Versus Balloon Pulmonary Angioplasty in Non-operable Chronic thromboEmbolic Pulmonary Hypertension Completed NCT02634203 Riociguat
45 Evaluation of Pulmonary Perfusion Heterogeneity in Patients With Chronic Thromboembolic Pulmonary Hypertension Using Functional PET Imaging Completed NCT02114047
46 Role of Inflammation and Angiogenesis in Chronic Thromboembolic Pulmonary Hypertension Completed NCT04472533
47 Efficacy of Medical Therapy for Pulmonary Arterial and Inoperable Chronic Thromboembolic Pulmonary Hypertension in a Real Life Setting Completed NCT03198910
48 EMEA CTEPH Registry: An International Prospective Registry Investigating the Epidemiology, Diagnosis and Treatment of CTEPH Patients in EMEA Countries Completed NCT02637050
49 Identification of CTEPH on Standard Computerised Tomography Pulmonary Angiography Performed in the Work-up of Suspected Pulmonary Embolism Completed NCT03083093
50 Retrospective Chart Review of Patients With PAH or Inoperable/Persistent/Recurrent CTEPH Who Transition Their PH Treatment to Adempas Completed NCT02545465 Riociguat (Adempas, BAY63-2521)

Search NIH Clinical Center for Pulmonary Hypertension, Chronic Thromboembolic, Without Deep Vein Thrombosis

Genetic Tests for Pulmonary Hypertension, Chronic Thromboembolic, Without Deep Vein...

Anatomical Context for Pulmonary Hypertension, Chronic Thromboembolic, Without Deep Vein...

MalaCards organs/tissues related to Pulmonary Hypertension, Chronic Thromboembolic, Without Deep Vein Thrombosis:

40
Endothelial, Lung, Smooth Muscle, Heart, Neutrophil, Kidney, Lymph Node

Publications for Pulmonary Hypertension, Chronic Thromboembolic, Without Deep Vein...

Articles related to Pulmonary Hypertension, Chronic Thromboembolic, Without Deep Vein Thrombosis:

(show top 50) (show all 2114)
# Title Authors PMID Year
1
HLA-DPB1 and NFKBIL1 may confer the susceptibility to chronic thromboembolic pulmonary hypertension in the absence of deep vein thrombosis. 57 61
19165231 2009
2
How should a physician approach the pharmacological management of chronic thromboembolic pulmonary hypertension? 61
33016151 2021
3
Plasma metabolomics exhibit response to therapy in chronic thromboembolic pulmonary hypertension. 61
33060150 2021
4
From Health-Related Quality of Life (HRQoL) of Patients with Pulmonary Hypertension to Patient Experience with the Care Received: Should We Be More Aware of Current Patient Needs? 61
33675523 2021
5
Preoperative C-reactive protein predicts early postoperative outcomes after pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension. 61
32007254 2021
6
Vascular Endobronchial Ultrasound in a Patient With Chronic Thromboembolic Pulmonary Hypertension. 61
33753706 2021
7
Chronic thromboembolic pulmonary hypertension: evaluation of V/Q SPECT/CT and V/Q Quotient SPECT findings with postoperative results of pulmonary endarterectomy. 61
33443395 2021
8
Retraction notice to ICAM-1 PROMOTES THE ABNORMAL ENDOTHELIAL CELL PHENOTYPE IN CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION. 61
33810826 2021
9
Commentary: Chronic thromboembolic pulmonary hypertension and the misguided thrombus. 61
32005578 2021
10
Commentary: Biomarkers in chronic thromboembolic pulmonary hypertension-The clot thickens. 61
32089345 2021
11
Evaluating the Right Ventricle in Acute and Chronic Pulmonary Embolism: Current and Future Considerations. 61
33548932 2021
12
Determinants and Management of the Post-Pulmonary Embolism Syndrome. 61
33548930 2021
13
Association between Preoperative Dynamic Measures of Vascular Load and Postoperative Hemodynamics in Patients with Chronic Thromboembolic Pulmonary Hypertension after Pulmonary Thromboendarterectomy. 61
33141597 2021
14
Balloon Pulmonary Angioplasty in Technically Operable and Technically Inoperable Chronic Thromboembolic Pulmonary Hypertension. 61
33802475 2021
15
The role of balloon pulmonary angioplasty and pulmonary endarterectomy: Is chronic thromboembolic pulmonary hypertension still a life-threatening disease? 61
33086125 2021
16
Protein network analyses of pulmonary endothelial cells in chronic thromboembolic pulmonary hypertension. 61
33692478 2021
17
Improvement after bariatric surgery in chronic thromboembolic pulmonary hypertension: a novel treatment target. 61
33746114 2021
18
Non-invasive early exclusion of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: the InShape II study. 61
33758073 2021
19
Continual Improvement in Pressure Gradient at the Lesion after Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension. 61
33744368 2021
20
Assessment of oxygenation after balloon pulmonary angioplasty for patients with inoperable chronic thromboembolic pulmonary hypertension. 61
33684382 2021
21
The role of β-catenin in pulmonary artery endothelial-mesenchymal transformation in rats with chronic thromboembolic pulmonary hypertension. 61
33655472 2021
22
Chronic thromboembolic pulmonary hypertension risk score evaluation and validation (CTEPH Solution): proposal of a study protocol aimed to realize a validated risk score for early diagnosis. 61
33703863 2021
23
Right Ventricular Extracellular Volume with Dual-Layer Spectral Detector CT: Value in Chronic Thromboembolic Pulmonary Hypertension. 61
33497315 2021
24
Pulmonary angioplasty: A step further in the continuously changing landscape of chronic thromboembolic pulmonary hypertension management. 61
33524919 2021
25
CLINICAL IMPLICATIONS OF BODY COMPOSITION AND EXERCISE CAPACITY FOLLOWING PULMONARY ENDARTERECTOMY. 61
33667463 2021
26
Three treatment options and the combination for patients with chronic thromboembolic pulmonary hypertension - established or not. 61
33221350 2021
27
Efficacy and safety of balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension. 61
33032905 2021
28
Successful use of intravenous treprostinil as a bridge to pulmonary thromboendarterectomy. 61
33766958 2021
29
Gadolinium contrast balloon pulmonary angioplasty for a patient with chronic thromboembolic pulmonary hypertension and severe iodine allergy. 61
32478464 2021
30
Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry. 61
33540340 2021
31
High CD200 Expression on T CD4+ and T CD8+ Lymphocytes as a Non-Invasive Marker of Idiopathic Pulmonary Hypertension-Preliminary Study. 61
33804413 2021
32
Inspiratory Muscle Training Improves Inspiratory Muscle Strength and Functional Exercise Capacity in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: A Pilot Randomised Controlled Study. 61
32736963 2021
33
Effect of Supervised Training Therapy on Pulmonary Arterial Compliance and Stroke Volume in Severe Pulmonary Arterial Hypertension and Inoperable or Persistent Chronic Thromboembolic Pulmonary Hypertension. 61
33765679 2021
34
Chronic Thromboembolic Disease and Chronic Thromboembolic Pulmonary Hypertension. 61
33541619 2021
35
Left upper lobe trisegmentectomy after pulmonary endarterectomy. 61
33662316 2021
36
Haemodynamic benefit of bridging use of bosentan prior to pulmonary endarterectomy. 61
33755096 2021
37
Computed tomography angiographic parameters of pulmonary artery as prognostic factors of residual pulmonary hypertension after pulmonary endarterectomy. 61
33761801 2021
38
The Inflammatory Profile of CTEPH-Derived Endothelial Cells Is a Possible Driver of Disease Progression. 61
33810533 2021
39
Do right heart hemodynamic improvements persist after pulmonary thromboendarterectomy? 61
33691188 2021
40
Right ventricular adaptation to pressure-overload: Differences between chronic thromboembolic pulmonary hypertension and idiopathic pulmonary arterial hypertension. 61
33745783 2021
41
Pulmonary atherosclerosis in a patient with chronic thromboembolic pulmonary hypertension. 61
33316138 2021
42
Balloon pulmonary angioplasty in the treatment of chronic thromboembolic pulmonary hypertension: recent advances and future perspectives. 61
33463996 2021
43
Association between splenectomy and chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis. 61
33622936 2021
44
Risk stratification in chronic thromboembolic pulmonary hypertension predicts survival. 61
32586166 2021
45
Evolution of patients with chronic thromboembolic pulmonary hypertension treated by balloon pulmonary angioplasty, according to their anticoagulant regimens. 61
33582861 2021
46
Treatment effect prediction using CT after balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension. 61
33569619 2021
47
Correlation Between Perfusion Abnormalities Extent in Ventilation/Perfusion SPECT/CT with Hemodynamic Parameters in Patients with Chronic Thromboembolic Pulmonary Hypertension 61
33586404 2021
48
Successful intravascular pulmonary lithotripsy in a child with chronic thromboembolic pulmonary hypertension. 61
33634582 2021
49
Systematic Staged Percutaneous Balloon Pulmonary Angioplasty in Severe Inoperable Chronic Thromboembolic Pulmonary Hypertension. 61
33566998 2021
50
Characteristics and long-term survival of patients with chronic thromboembolic pulmonary hypertension in China. 61
32954622 2021

Variations for Pulmonary Hypertension, Chronic Thromboembolic, Without Deep Vein...

Expression for Pulmonary Hypertension, Chronic Thromboembolic, Without Deep Vein...

Search GEO for disease gene expression data for Pulmonary Hypertension, Chronic Thromboembolic, Without Deep Vein Thrombosis.

Pathways for Pulmonary Hypertension, Chronic Thromboembolic, Without Deep Vein...

GO Terms for Pulmonary Hypertension, Chronic Thromboembolic, Without Deep Vein...

Sources for Pulmonary Hypertension, Chronic Thromboembolic, Without Deep Vein...

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....